CEBPB and Hepatic fibrosis: C/EBPβ+/+ mice with severe liver fibrosis induced by an 8-week CCl4 treatment, while continuing on CCl4, were treated with a cell permeant RSK-inhibitory peptide for 4 or 8 weeks.